Autopsy report · NCT04762160

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

“Decision to terminate EZH-1401 was solely due to company business decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 1 year 3 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Epizyme, Inc.

Sponsor type

Industry

Conditions

Follicular Lymphoma

Interventions

Tazemetostat; Rituximab

Participants

5

Sites

20

Countries

United States

Trials that died the same way

• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
  “The Relamorelin program is being terminated solely based on a business decision.” (63% match in meaning)
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
  “The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.